BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/20/2014 7:04:00 PM | Browse: 1030 | Download: 1574
Publication Name World Journal of Clinical Pediatrics
Manuscript ID 12095
Country/Territory Saudi Arabia
Received
2014-06-22 12:51
Peer-Review Started
2014-06-22 22:35
To Make the First Decision
2014-08-14 15:01
Return for Revision
2014-08-19 09:01
Revised
2014-09-02 05:46
Second Decision
2014-10-27 16:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-10-27 17:12
Articles in Press
2014-10-27 17:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-04 16:46
Publish the Manuscript Online
2014-11-20 19:04
ISSN 2219-2808 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Minireviews
Article Title Rituximab for troublesome cases of childhood nephrotic syndrome
Manuscript Source Invited Manuscript
All Author List Osama Y Safdar, Adila Aboualhameael and Jameela A Kari
Funding Agency and Grant Number
Corresponding Author Jameela A Kari, FRCP, MD, Department of Pediatrics, King Abdulaziz University, PO Box 80215, Jeddah 21589, Saudi Arabia. jkari@kau.edu.sa
Key Words Rituximab; Pediatric; Nephrotic syndrome; Efficacy; Safety
Core Tip Nephrotic syndrome (NS) is the most common pediatric glomerular disease. Although outcomes are favorable, the treatment of complicated nephrotic syndrome can be challenging. Rituximab (RTX) offers a safe and effective alternative to current immunosuppressive therapies for complicated cases of NS. The best outcomes are seen in patients with steroid-dependent NS who have failed to respond to multiple therapies. However, the benefits of RTX therapy are limited in patients with steroid-resistant nephrotic syndrome. Successful RTX therapy induces prolonged remission and enables discontinuation of other medications without increasing the risk of infection and other adverse events.
Publish Date 2014-11-20 19:04
Citation Safdar OY, Aboualhameael A, Kari JA. Rituximab for troublesome cases of childhood nephrotic syndrome. World J Clin Pediatr 2014; 3(4): 69-75
URL http://www.wjgnet.com/2219-2808/full/v3/i4/69.htm
DOI http://dx.doi.org/10.5409/wjcp.v3.i4.69
Full Article (PDF) WJCP-3-69.pdf
Full Article (Word) WJCP-3-69.doc
Manuscript File 12095-Review.docx
Answering Reviewers 12095-Answering reviewers.pdf
Copyright License Agreement 12095-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 12095-Language certificate.pdf
Peer-review Report 12095-Peer review(s).pdf
Scientific Misconduct Check 12095-CrossCheck.jpg
Scientific Editor Work List 12095-Scientific editor work list.pdf